Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$21,869 Mln
Revenue (TTM)
$13,952 Mln
Net Profit (TTM)
$877 Mln
ROE
0.1 %
ROCE
5.6 %
P/E Ratio
25.2
P/B Ratio
2.5
Industry P/E
--
EV/EBITDA
13.8
Div. Yield
1.1 %
Debt to Equity
0.8
Book Value
$103.6
EPS
$10.5
Face value
--
Shares outstanding
82,400,000
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Labcorp Holdings
| 6.0 | -3.9 | 3.9 | 10.6 | 13.2 | 5.3 | 10.7 |
|
BSE Sensex*
| -12.4 | -11.4 | -12.2 | -1.5 | 8.6 | 8.6 | 11.5 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Labcorp Holdings
| 9.4 | 0.9 |
|
S&P 100
| 18.7 | 29.0 |
|
BSE Sensex
| 9.1 | 8.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Labcorp Holdings
|
265.8 | 21,869.0 | 13,951.7 | 876.5 | 9.5 | 10.5 | 25.2 | 2.5 |
| 73.0 | 96,853.4 | 402,067.0 | 1,768.0 | 1.3 | 2.3 | 54.8 | 1.3 | |
| 99.7 | 10,098.8 | 5,935.2 | 566.2 | 18.1 | 25.1 | 18.1 | 4.1 | |
| 70.7 | 2,278.1 | 427.5 | -21.0 | -4.4 | -7.6 | -- | 7.4 | |
| 502.1 | 119,183.9 | 75,600.0 | 6,784.0 | 16.0 | -159.1 | 18.8 | 293.4 | |
| 197.8 | 26,624.2 | 2,306.1 | -208.2 | -11.2 | -14.3 | -- | 15.5 | |
| 195.2 | 22,215.1 | 11,035.0 | 992.0 | 13.2 | 14.2 | 22.8 | 3.1 | |
| 203.2 | 20,005.3 | 21,310.0 | 1,407.0 | 16.9 | 33.5 | 14.7 | 4.6 | |
| 205.0 | 12,186.8 | 5,057.8 | 344.0 | 9.2 | 16.9 | 36 | 5.5 | |
| 189.6 | 11,754.3 | 17,364.8 | 1,488.8 | 12.2 | 21.4 | 8.3 | 1.6 |
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts,... thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company was founded in 1995 and is headquartered in Burlington, North Carolina. Read more
President, CEO & Chairman
Mr. Adam H. Schechter
President, CEO & Chairman
Mr. Adam H. Schechter
Headquarters
Burlington, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Labcorp Holdings Inc is $265.84 (NYSE) as of 18-Mar-2026 16:28 EDT. Labcorp Holdings Inc has given a return of 13.2% in the last 3 years.
The P/E ratio of Labcorp Holdings Inc is 25.20 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
23.81
|
2.42
|
|
2024
|
25.88
|
2.40
|
|
2023
|
46.16
|
2.45
|
|
2022
|
16.38
|
2.08
|
|
2021
|
12.71
|
2.94
|
The 52-week high and low of Labcorp Holdings Inc are Rs 293.72 and Rs 209.38 as of 19-Mar-2026.
Labcorp Holdings Inc has a market capitalisation of $ 21,869 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Labcorp Holdings Inc, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-4.78
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.